Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Prime Minister Abe Asks Ministries to Begin Discussions Toward Establishing Japanese Version of NIH
April 2, 2013
- Hodanren Calls for Inclusion of Pharmacies’ Technical Fees in Domestic Drug Prices When Comparing Drug Prices in Japan, US, and Europe
April 1, 2013
- MOF Budget Examiner Hirotsugu Shinkawa Hopes to See New Generic Target Set at Highest Share Achievable at Fastest Pace
March 29, 2013
- MHLW’s Generic Roadmap Compilation in Homestretch
March 29, 2013
- MHLW Committee Calls for New Name for Norvasc or Nolvadex to Prevent Further Prescribing Errors
March 29, 2013
- PFSB Notification Calls for Revisions of Precautions for Gabapentin, Other Drugs
March 28, 2013
- MHLW to Request Development of 2 Unapproved Indications Determined to Have Unmet Medical Needs
March 27, 2013
- PAFSC Committee Approves Reclassification of Tiquizium Bromide and Diclofenac as Class 2 OTC Drugs
March 26, 2013
- Administrative Evaluation: Health Ministry Urged to Review All-Specification Listing Requirement for Generics
March 25, 2013
- LDP Subcommittee Begins Discussions on Amending PAL; Bill Expected to Be Submitted During Current Diet Session
March 25, 2013
- Regulatory Reform Council Not Convinced of MHLW’s Response to Online Sale of OTC Drugs
March 25, 2013
- CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together
March 22, 2013
- PMDA’s FY2013 Project Plan OK’d; Discussions for 3rd Mid-Term Plan to Get Underway
March 21, 2013
- Government’s New Office to Compile Health and Medical Strategy by June, Appoints JPMA Teshirogi as Advisor
March 21, 2013
- PMDA Testing New System that Uses Electronic Medical Information to Help Assess Post-Marketing Drug Risk
March 21, 2013
- MHLW Announces 4-Year Extension of Reexamination Period for Adoair
March 21, 2013
- MHLW Issues Notification on Revised GVP, GPSP Ordinances
March 19, 2013
- LDP to Begin Discussions on Bill to Amend PAL; MHLW Aims to Submit Bill during Current Diet Session
March 19, 2013
- Payer Representative Tsuyoshi Kobayashi Questions Automatic Health Insurance Coverage for Additional Indications
March 15, 2013
- Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future
March 15, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…